Exchange: NASDAQ·Updated 12:50 PM EDT
BCRX logo

BCRXBiocryst Pharmaceuticals Inc.

$9.86
$0.05
(0.51%)
Today
EarningsAug 3
Mkt Cap$2.52B
Vol999,917.00
News
all
press releases
Wall Street Analysts Think BioCryst (BCRX) Could Surge 117.96%: Read This Before Placing a Bet
The consensus price target hints at an 118% upside potential for BioCryst (BCRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks
News Placeholder
More News
News Placeholder
Why Did PENG, ANET, BCRX Shares Surge To 52-Week Highs?
Penguin Solutions, Arista Networks, and Biocryst Pharmaceuticals surged to 52-week highs on Wednesday amid a rotation into technology and healthcare stocks.
Stocktwits
News Placeholder
BioCryst (BCRX) Surges 8.1%: Is This an Indication of Further Gains?
BioCryst (BCRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Zacks
News Placeholder
VKTX Vs BCRX: Which Biotech Takeover Favorite Offers More Upside After Vertex’s $10B CRNX Deal?
Wall Street sees bigger upside in VKTX, with Koyfin’s average target implying 120% upside versus 99% for BCRX.
Stocktwits
News Placeholder
Why Did CRNX, D, BCRX Stocks Surge To 52-Week Highs Today?
Investors favored companies benefiting from biotech deals, rising power demand from AI data centers, and cost-cutting efforts to improve profits.
Stocktwits
News Placeholder
Ono Pharmaceutical Co. (OPHLF) Moves 10.4% Higher: Will This Strength Last?
Ono Pharmaceutical Co. (OPHLF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Zacks
News Placeholder
BCRX Stock Set For Best Week In Over 3 Months – Retail Shifts Focus To This Crucial Breakout Level
BCRX stock climbed past its key resistance at $10.32 to hit a record high earlier in the session, before paring most of the gains.
Stocktwits
News Placeholder
These Analysts Revise Their Forecasts On BioCryst Pharma After Q1 Earnings
BioCryst Pharma (NASDAQ:BCRX) reported strong Q1 earnings, reaffirmed FY2026 sales guidance, and received positive price target changes from analysts.read more...
Benzinga
News Placeholder
BioCryst Pharmaceuticals (NASDAQ:BCRX) Releases Earnings Results, Misses Expectations By $3.04 EPS
BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) announced its quarterly earnings data on Wednesday. The biotechnology company reported ($2.98) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.06 by ($3.04). The firm had revenue of $156.41 million during the...
MarketBeat
News Placeholder
BioCryst Pharmaceuticals (NASDAQ:BCRX) Price Target Cut to $16.00 by Analysts at Needham & Company LLC
Needham & Company LLC dropped their price objective on BioCryst Pharmaceuticals from $18.00 to $16.00 and set a "buy" rating for the company in a research report on Wednesday...
MarketBeat
<
1
2
...
>

Advertisement|Remove ads.